Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(165 produtos)
- Bcr-Abl(118 produtos)
- EGFR(586 produtos)
- FAK(72 produtos)
- FLT(89 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(180 produtos)
- JAK(245 produtos)
- PDGFR(129 produtos)
- RAAS(88 produtos)
- Src(82 produtos)
- Syk(37 produtos)
- Trombina(54 produtos)
- VDA(2 produtos)
- VEGFR(245 produtos)
Exibir 6 mais subcategorias
Foram encontrados 2275 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
SJ-C1044
CAS:SJ-C1044 is an orally effective pan-RAF inhibitor demonstrating immunomodulatory and antitumor activities. It targets wild-type BRAF, wild-type CRAF, and BRAF(V600E) with IC50 values of 331, 257, and 187 nM, respectively. SJ-C1044 suppresses tumor cell proliferation by inhibiting kras activation and MEK-ERK phosphorylation. Additionally, it shows inhibition of VEGFR2, TIE2, and CSF1R, with IC50 values of 100, 23, and 235 nM respectively. The compound enhances the tumor immune microenvironment through inhibition of angiogenesis and modulation of macrophage function. SJ-C1044 is applicable for research in colorectal cancer.Fórmula:C25H14F7N7OCor e Forma:SolidPeso molecular:561.41VEGFR-2-IN-26
CAS:VEGFR-2-IN-26 inhibits VEGFR-2 (IC50: 15.5 nM), combating various cancers' cell growth.Fórmula:C24H19F3N6O2Cor e Forma:SolidPeso molecular:480.44JAK-IN-19
JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).Fórmula:C26H36FN5O2Cor e Forma:SolidPeso molecular:469.59Tofacitinib Prodrug-1
Tofacitinib Prodrug-1: an oral prodrug reducing Tofacitinib's side effects, treats ulcerative colitis in mice effectively with low toxicity.Fórmula:C36H39ClN10O7Cor e Forma:SolidPeso molecular:759.21EGFR/HER2-IN-5
EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.Cor e Forma:SolidOxamic acid
CAS:Oxamic acid is an LDHA inhibitor, antitumor, induces apoptosis, downregulates EGFR expression, and inhibits cancer stem cell properties and EMT.Fórmula:C2H3NO3Cor e Forma:SolidPeso molecular:89.05JAK-2/3-IN-3
JAK-2-/3-IN-3 (ST4j) is a potent JAK2/3 inhibitor for leukemia research, with IC50s: JAK2, 13 nM; JAK3, 14.86 nM; induces apoptosis.Fórmula:C13H10Cl2N4O2Cor e Forma:SolidPeso molecular:325.15BMS-986143
CAS:BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.Fórmula:C31H24Cl2N4O4Cor e Forma:SolidPeso molecular:587.45JAK3/BTK-IN-4
CAS:JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)Fórmula:C21H25ClN8OCor e Forma:SolidPeso molecular:440.93MTX-216
CAS:MTX-216 is an ATP-competitive inhibitor targeting both PI3K and EGFR. It simultaneously inhibits Ki-67 and ribosomal S6 phosphorylation, inducing apoptosis in NF1LOF cells. Additionally, MTX-216 suppresses SYK kinase activity with an IC50 of 281 nM. This compound is applicable for melanoma research.Fórmula:C22H14Cl2FN5O2SCor e Forma:SolidPeso molecular:502.348BPI-15086
CAS:BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.Fórmula:C29H33ClN8O4Cor e Forma:SolidPeso molecular:593.08FLT3-IN-13
FLT3-IN-13 inhibits topoisomerase II/FLT3 in leukemia with IC50 of 2.26 μM, causes G2/M arrest, and promotes apoptosis.Fórmula:C20H14N4O2Cor e Forma:SolidPeso molecular:342.35Cernuumolide J
CAS:Cernuumolide J (TMJ-105) functions as a JAK2/STAT3 inhibitor and exhibits potent activity against HEL leukemia cells by inhibiting their growth in both time-dependent and concentration-dependent manners, with an IC 50 value of 1.79 μM. This compound effectively induces G2/M phase arrest and apoptosis by downregulating the phosphorylation of JAK2, STAT3, and Erk, while simultaneously upregulating the phosphorylation of JNK and p38 MAPK. Cernuumolide J holds potential for research applications in anti-cancer therapy.Fórmula:C24H34O8Cor e Forma:SolidPeso molecular:450.52FGFR-IN-16
CAS:FGFR-IN-16 (compound 7N) is a potent inhibitor of FGFR1, FGFR2, and FGFR4, exhibiting IC50 values of 8 nM, 4 nM, and 3.8 nM respectively. It plays a crucial role in cancer research.Fórmula:C30H27Cl2N7O4Cor e Forma:SolidPeso molecular:620.49EGFR-IN-146
CAS:EGFR-IN-146 is an EGFR inhibitor that suppresses the EGFR signaling pathway and improves insulin sensitivity by activating the AMPK pathway. It effectively reduces blood glucose levels and body weight, showing great potential in the study of diabetes and obesity.Fórmula:C20H16N4Cor e Forma:SolidPeso molecular:312.368Lomonitinib
CAS:Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor with antitumor properties. It shows promise for research in myeloid leukemia.
Fórmula:C27H24N4O2Cor e Forma:SolidPeso molecular:436.505FGFR-IN-15
FGFR-IN-15 (compound 18i) acts as a pan-FGFR inhibitor, exhibiting potent inhibitory activity against FGFR1-4.Fórmula:C22H23N5O5SCor e Forma:SolidPeso molecular:469.51HER2-IN-12
HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.Fórmula:C17H18BrN5O2SCor e Forma:SolidPeso molecular:436.33Tandutinib sulfate
CAS:Tandutinib (MLN518) sulfate is an effective and selective inhibitor of FLT3, with an IC50 value of 0.22 μM. It also inhibits c-Kit and PDGFR, displaying IC50 values of 0.17 μM and 0.20 μM respectively. This compound can be utilized in the treatment of acute myeloid leukemia and has the capability to cross the blood-brain barrier.Fórmula:C31H44N6O8SCor e Forma:SolidPeso molecular:660.78VEGFR-IN-3
CAS:VEGFR-IN-3 inhibits cancer cell growth (OVCAR-4, MDA-MB-468) with IC50s: 0.29, 0.35μM. Used in cancer research.Fórmula:C27H28N2O6Cor e Forma:SolidPeso molecular:476.52
